A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer
Fehrenbacher L, O’Neill V, Belani C, Bonomi P, Hart L, Melnyk O, Sandler A, Ramies D, Herbst R. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Journal Of Clinical Oncology 2006, 24: 7062-7062. DOI: 10.1200/jco.2006.24.18_suppl.7062.Peer-Reviewed Original ResearchDisease progressionArm 1Single-arm phase I/II studyRefractory non-small cell lung cancerPhase I/II studyNon-small cell lung cancerRandomized phase II trialEGFR tyrosine kinase inhibitorsAnti-VEGF mAbsPlatinum-based regimenSafety of bevacizumabCombination of bevacizumabFirst-line settingNon-squamous NSCLCAdvanced stage diseaseAvailable EGFR tyrosine kinase inhibitorsPhase II trialProgression-free survivalTreatment of recurrentCell lung cancerClinical disease progressionFavorable safety profileTreatment of NSCLCTyrosine kinase inhibitorsAdenocarcinoma/